journal article·2018-02-23Open access

Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications

Parham Sahandi Zangabad, Soroush Mirkiani, Shayan Shahsavari, Behrad Masoudi, Maryam Masroor, Hamid Hamed, Zahra Jafari, Yasamin Davatgaran Taghipour, Hura Hashemi, Mahdi Karimi, Michael R. Hamblin

Nanotechnology Reviews· Volume 7· Issue 1

Abstract

Abstract Liposomes are known to be promising nanoparticles (NPs) for drug delivery applications. Among the different types of self-assembled NPs, liposomes stand out for their non-toxic nature and their possession of dual hydrophilic-hydrophobic domains. The advantages of liposomes include the ability to solubilize hydrophobic drugs, the ability to incorporate different hydrophilic and lipophilic drugs at the same time, lessening the exposure of host organs to potentially toxic drugs and allowing modification of the surface by a variety of different chemical groups. This modification of the surface, or of the individual constituents, may be used to achieve two important goals. First, ligands for active targeting can be attached that are recognized by cognate receptors overexpressed on the target cells of tissues. Second, modification can be used to impart a stimulus-responsive or “smart” character to the liposomes, whereby the cargo is released on demand only when certain internal stimuli (pH, reducing agents, specific enzymes) or external stimuli [light, magnetic field, or ultrasound (US)] are present. Here, we review the field of smart liposomes for drug delivery applications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Center for Pharmaceutical Nanotechnology (RCPN) , Tabriz University of Medical Science (TUOMS) , Tabriz , Iran

Cellular and Molecular Research Center , Iran University of Medical Sciences , Tehran , Iran

Bio-Nano Interfaces: Convergence of Sciences (BNICS) , Universal Scientific Education and Research Network (USERN) , Tehran , Iran

Advanced Nanobiotechnology and Nanomedicine Research Group (ANNRG) , Iran University of Medical Sciences , Tehran , Iran

Nanomedicine Research Association (NRA) , Universal Scientific Education and Research Network (USERN) , Tehran , Iran

Bioceramics and Implants Laboratory , Department of Life Science Engineering, Faculty of New Sciences and Technologies , University of Tehran , Tehran 1439955941 , Iran

Nanoclub Elites Association, Iran Nanotechnology Initiative Council , Tehran , Iran

Mataab Company, Biotechnology Incubator, Production and Research Complex, Pasteur Institute of Iran , Karaj , Iran

School of Chemistry, College of Science , University of Tehran , Tehran , Iran

School of Metallurgy and Materials Engineering, College of Engineering , University of Tehran , Tehran , Iran

Petroleum and Chemical Engineering Department , Sharif University of Technology , Tehran , Iran

Department of Food Science and Technology, College of Agriculture and Food Science, Ayatollah Amoli Branch , Islamic Azad University , Amol , Iran

Department of Medical Nanotechnology, School of Advanced Technologies in Medicine , Tehran University of Medical Sciences , Tehran , Iran

Faculty of Pharmacy , Tehran University of Medical Sciences , P. O. Box 14155-6451 , Tehran , Iran

Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine , Iran University of Medical Sciences , Tehran , Iran

Research Center for Science and Technology in Medicine , Tehran University of Medical Sciences , Tehran , Iran

Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School , Boston, MA , USA

Department of Dermatology, Harvard Medical School , Boston, MA , USA

Harvard-MIT Division of Health Sciences and Technology , Cambridge, MA , USA

References (100+)

Show source-provided references
1. Karimi M, Zare H, Bakhshian Nik A, Yazdani N, Hamrang M, Mohamed E, Sahandi Zangabad P, Moosavi Basri SM, Bakhtiari L, Hamblin MR. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine 2016, 11, 513–530.10.2217/nnm.16.3 ↗
2. Karimi M, Ghasemi A, Sahandi Zangabad P, Rahighi R, Moosavi Basri SM, Mirshekari H, Amiri M, Pishabad ZS, Aslani A, Bozorgomid M, Ghosh D. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem. Soc. Rev. 2016, 45, 1457–1501.
3. Sahandi Zangabad P, Karimi M, Mehdizadeh F, Malekzad H, Ghasemi A, Bahrami S, Zare H, Moghoofei M, Hekmatmanesh A, Hamblin MR. Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger. Nanoscale 2017, 9, 1356–1392.10.1039/C6NR07315H ↗
4. Karimi M, Sahandi Zangabad P, Baghaee-Ravari S, Ghazadeh M, Mirshekari H, Hamblin MR. Smart nanostructures for cargo delivery: uncaging and activating by light. J. Am. Chem. Soc. 2017, 139, 4584–4610.
5. Karimi M, Zangabad PS, Ghasemi A, Hamblin MR. Smart External Stimulus-Responsive Nanocarriers for Drug and Gene Delivery, Morgan & Claypool Publishers: San Rafael, CA, USA, 2015, ISBN: 978-1-6817-4202-1.10.1088/978-1-6817-4202-1ch4 ↗
6. Karimi M, Zangabad PS, Ghasemi A, Hamblin MR. Smart Internal Stimulus-Responsive Nanocarriers for Drug and Gene Delivery: IOP Concise Physics, 2015. ISBN: 978-1-6817-4257-1. doi: 10.1088/978-1-6817-4202-1.10.1088/978-1-6817-4202-1 ↗
7. Barar J, Aghanejad A, Fathi M, Omidi Y. Advanced drug delivery and targeting technologies for the ocular diseases. Bioimpacts 2016, 6, 49.10.15171/bi.2016.07 ↗
8. Massoumi B, Poorgholy N, Jaymand M. Multistimuli responsive polymeric nanosystems for theranostic applications. Int. J. Polym. Mater. Polym. Biomater. 2017, 66, 38–47.
9. Karimi M, Moosavi Basri SM, Vossoughi M, Pakchin PS, Mirshekari H, Hamblin MR. Redox-sensitive smart nanosystems for drug and gene delivery. Curr. Org. Chem. 2016, 20, 2949–2959.
10. Karimi M, Bahrami S, Ravari SB, Zangabad PS, Mirshekari H, Bozorgomid M, Shahreza S, Sori M, Hamblin MR. Albumin nanostructures as advanced drug delivery systems. Exp. Opin. Drug Deliv. 2016, 13, 1609–1623.
11. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res. Lett. 2013, 8, 1.
12. Bangham A, Standish MM, Watkins J. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13, 238–IN27.
13. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem. Rev. 2015, 115, 10938–10966.
14. Deshmukh RR, Gawale SV, Bhagwat MK, Ahire PA, Derle ND. A review on: liposomes. World J. Pharm. Pharm. Sci. 2016, 5, 506–517.
15. Jone A. Liposomes: a short review. J. Pharm. Sci. Res. 2013, 5, 181–183.
16. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145–160.10.1038/nrd1632 ↗
17. Barhoumi A, Liu Q, Kohane DS. Ultraviolet light-mediated drug delivery: principles, applications, and challenges. J. Control. Release 2015, 219, 31–42.10.1016/j.jconrel.2015.07.018 ↗
18. Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160, 117–134.10.1016/j.jconrel.2012.03.020 ↗
19. Barenholz YC. Doxil®–the first FDA-approved Nano-drug: from basics via CMC, cell culture and animal studies to clinical use. In Nanomedicines: Design, Delivery and Detection, Braddock, M, Ed., RSC Publishing: London, UK, 2016, 51, pp. 315–345. Available at: http://pubs.rsc.org/en/content/chapter/bk9781849739474-00315/978-1-84973-947-4.10.1039/9781782622536-00315 ↗
20. Leonard R, Williams S, Tulpule A, Levine A, Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet™). Breast 2009, 18, 218–224.10.1016/j.breast.2009.05.004 ↗
21. Swenson C, Perkins W, Roberts P, Janoff A. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). Breast 2001, 10, 1–7.10.1016/S0960-9776(01)80001-1 ↗
22. Chou H-H, Wang K-L, Chen C-A, Wei L-H, Lai C-H, Hsieh C-Y, Yang YC, Twu NF, Chang TC, Yen MS. Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol. Oncol. 2006, 101, 423–428.
23. Smith JA, Mathew L, Burney M, Nyshadham P, Coleman RL. Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model. Gynecol. Oncol. 2016, 141(2), 357–363.
24. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk. Lymphoma 2005, 46, 795–802.10.1080/10428190500052438 ↗
25. Petre CE, Dittmer DP. Liposomal daunorubicin as treatment for Kaposi’s sarcoma. Int. J. Nanomed. 2007, 2, 277.
26. Silverman JA, Deitcher SR. Marqibo®(vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 2013, 71, 555–564.
27. Sarris A, Hagemeister F, Romaguera J, Rodriguez M, McLaughlin P, Tsimberidou A, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H. Liposomal vincristine in relapsed non-Hodgkin’s lymphomas: early results of an ongoing phase II trial. Ann. Oncol. 2000, 11, 69–72.
28. Rodriguez M, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma. Cancer 2009, 115, 3475–3482.10.1002/cncr.24359 ↗
29. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, van Burik JA, Laverdiere M, Safrin S, Wingard JR. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 2002, 35, 359–366.
30. Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations—Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet—against systemic murine aspergillosis. Antimicrob. Agents Chemother. 2004, 48, 1047–1050.
31. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999, 5, 3394–3402.
32. Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J. Neuro-oncol. 2012, 109, 143–148.10.1007/s11060-012-0880-x ↗
33. Simon JA, Group ES. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006, 13, 222–231.10.1097/01.gme.0000174096.56652.4f ↗
34. Gambling D, Hughes T, Martin G, Horton W, Manvelian G, Group S-DES. A comparison of Depodur™, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth. Analg. 2005, 100, 1065–1074.
35. Carvalho B, Roland LM, Chu LF, Campitelli III VA, Riley ET. Single-dose, extended-release epidural morphine (DepoDur™) compared to conventional epidural morphine for post-cesarean pain. Anesth. Analg. 2007, 105, 176–813.
36. Keck S, Glennon C, Ginsberg B. DepoDur® extended-release epidural morphine: reshaping postoperative care: what perioperative nurses need to know. Orthop. Nurs. 2007, 26, 86–93.
37. Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am. J. Ophthalmol. 2001, 131, 518–520.
38. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv. Ophthalmol. 2005, 50, 167–182.
39. Bovier PA. Epaxal®: a virosomal vaccine to prevent hepatitis A infection. Exp. Rev. Vaccines 2008, 7, 1141–1150.10.1586/14760584.7.8.1141 ↗
40. Riedemann S, Reinhardt G, Ibarra H, Frösner G. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile. Acta Paediatr. 2004, 93, 412–414.
41. Feng Y, Fuentes D. Model-based planning and real-time predictive control for laser-induced thermal therapy. Int. J. Hyperthermia 2011, 27, 751–761.10.3109/02656736.2011.611962 ↗
42. Akimoto J, Nakayama M, Okano T. Temperature-responsive polymeric micelles for optimizing drug targeting to solid tumors. J. Control. Release 2014, 193, 2–8.10.1016/j.jconrel.2014.06.062 ↗
43. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, Felix R, Schlag PM. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002, 3, 487–497.
44. Dicheva BM, Koning GA. Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors. Exp. Opin. Drug Deliv. 2014, 11, 83–100.
45. Kono K. Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 2001, 53, 307–319.10.1016/S0169-409X(01)00204-6 ↗
46. Kawakami K, Ebara M, Izawa H, Sanchez-Ballester NM, Hill JP, Ariga K. Supramolecular approaches for drug development. Curr. Med. Chem. 2012, 19, 2388–2398.
47. Mallick S, Choi JS. Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. J. Nanosci. Nanotechnol. 2014, 14, 755–765.
48. Ta T, Porter TM. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J. Control. Release 2013, 169, 112–125.10.1016/j.jconrel.2013.03.036 ↗
49. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202, 1290–1293.10.1126/science.364652 ↗
50. Weinstein J, Magin R, Yatvin M, Zaharko D. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science 1979, 204, 188–191.10.1126/science.432641 ↗
51. Unezaki S, Maruyama K, Takahashi N, Koyama M, Yuda T, Suginaka A, Iwatsuru M. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm. Res. 1994, 11, 1180–5.
52. Levacheva I, Samsonova O, Tazina E, Beck-Broichsitter M, Levachev S, Strehlow B, Baryshnikova M, Oborotova N, Baryshnikov A, Bakowsky U. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof. Colloids Surf. B Biointerfaces 2014, 121, 248–256.10.1016/j.colsurfb.2014.02.028 ↗
53. Wardlow R, Bing C, VanOsdol J, Maples D, Ladouceur-Wodzak M, Harbeson M, Nofiele J, Staruch R, Ramachandran A, Malayer J, Chopra R. Targeted antibiotic delivery using low temperature-sensitive liposomes and magnetic resonance-guided high-intensity focused ultrasound hyperthermia. Int. J. Hyperthermia 2016, 32, 254–264.10.3109/02656736.2015.1134818 ↗
54. Anyarambhatla GR, Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature-sensitive liposome for use with mild hyperthermia. J. Liposome Res. 1999, 9, 491–506.
55. Musyanovych A, Landfester K. Polymer micro- and nanocapsules as biological carriers with multifunctional properties. Macromol. Biosci. 2014, 14, 458–477.
56. Fathi M, Entezami AA, Pashaei-Asl R. Swelling/deswelling, thermal, and rheological behavior of PVA-g-NIPAAm nanohydrogels prepared by a facile free-radical polymerization method. J. Polym. Res. 2013, 20, 1–11.
57. Karimi M, Sahandi Zangabad P, Ghasemi A, Amiri M, Bahrami M, Malekzad H, Ghahramanzadeh Asl H, Mahdieh Z, Bozorgomid M, Ghasemi A, Rahmani Taji Boyuk MR. Temperature-responsive smart nanocarriers for delivery of therapeutic agents: applications and recent advances. ACS Appl. Mater. Interfaces 2016, 8, 21107–21133.10.1021/acsami.6b00371 ↗
58. Pippa N, Meristoudi A, Pispas S, Demetzos C. Temperature-dependent drug release from DPPC: C 12 H 25-PNIPAM-COOH liposomes: control of the drug loading/release by modulation of the nanocarriers’ components. Int. J. Pharm. 2015, 485, 374–382.
59. Turner DC, Moshkelani D, Shemesh CS, Luc D, Zhang H. Near-infrared image-guided delivery and controlled release using optimized thermosensitive liposomes. Pharm. Res. 2012, 29, 2092–2103.
60. Guo H, Kim J-C. Upper critical solution temperature behavior of cinnamic acid and polyethyleneimine mixture and its effect on temperature-dependent release of liposome. Int. J. Pharm. 2015, 494, 172–179.
61. Lee S-M, Nguyen ST. Smart nanoscale drug delivery platforms from stimuli-responsive polymers and liposomes. Macromolecules 2013, 46, 9169–9180.10.1021/ma401529w ↗
62. Cao Z, Ma Y, Yue X, Li S, Dai Z, Kikuchi J. Stabilized liposomal nanohybrid cerasomes for drug delivery applications. Chem. Commun. 2010, 46, 5265–5267.
63. Ma Y, Dai Z, Gao Y, Cao Z, Zha Z, Yue X, Kikuchi JI. Liposomal architecture boosts biocompatibility of nanohybrid cerasomes. Nanotoxicology 2011, 5, 622–635.10.3109/17435390.2010.546950 ↗
64. Liang X, Li X, Jing L, Xue P, Jiang L, Ren Q, Dai Z. Design and synthesis of lipidic organoalkoxysilanes for the self-assembly of liposomal nanohybrid cerasomes with controlled drug release properties. Chemistry 2013, 19, 16113–16121.10.1002/chem.201302518 ↗
65. Yue X, Dai Z. Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers. Adv. Colloid Interface Sci. 2014, 207, 32–42.
66. Liang X, Gao J, Jiang L, Luo J, Jing L, Li X, Jin Y, Dai Z. Nanohybrid liposomal cerasomes with good physiological stability and rapid temperature responsiveness for high intensity focused ultrasound triggered local chemotherapy of cancer. ACS Nano 2015, 9, 1280–1293.10.1021/nn507482w ↗
67. Kono K, Takashima M, Yuba E, Harada A, Hiramatsu Y, Kitagawa H, Otani T, Maruyama K, Aoshima S. Multifunctional liposomes having target specificity, temperature-triggered release, and near-infrared fluorescence imaging for tumor-specific chemotherapy. J. Control. Release 2015, 216, 69–77.10.1016/j.jconrel.2015.08.005 ↗
68. Shin DH, Koo M-J, Kim JS, Kim J-S. Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer. Arch. Pharm. Res. 2016, 39, 350–358.
69. Patra S, Roy E, Madhuri R, Sharma PK. Creation of ultrasound and temperature-triggered bubble liposomes from economical precursors to enhance the therapeutic efficacy of curcumin in cancer cells. RSC Adv. 2016, 6, 85473–85485.
70. Mathiyazhakan M, Yang Y, Liu Y, Zhu C, Liu Q, Ohl C-D, Tam KC, Gao Y, Xu C. Non-invasive controlled release from gold nanoparticle integrated photo-responsive liposomes through pulse laser induced microbubble cavitation. Colloids Surf. B Biointerfaces 2015, 126, 569–574.10.1016/j.colsurfb.2014.11.019 ↗
71. Weissleder R. A clearer vision for in vivo imaging. Nat. Biotechnol. 2001, 19, 316–317.10.1038/86684 ↗
72. McCoy CP, Edwards CR, Jones DS, Gorman SP. Light-triggered molecule-scale drug dosing devices. J. Am. Chem. Soc. 2007, 129, 9572–9573.
73. Alvarez-Lorenzo C, Bromberg L, Concheiro A. Light-sensitive intelligent drug delivery systems. Photochem. Photobiol. 2009, 85, 848–860.
74. Jiang J, Qi B, Lepage M, Zhao Y. Polymer micelles stabilization on demand through reversible photo-cross-linking. Macromolecules 2007, 40, 790–792.10.1021/ma062493j ↗
75. He J, Tong X, Zhao Y. Photoresponsive nanogels based on photocontrollable cross-links. Macromolecules 2009, 42, 4845–4852.10.1021/ma900665v ↗
76. Lin B, Zhou S. Light-responsive nanoparticles with wettability changing from hydrophobicity to hydrophilicity and their application towards highly hydrophilic fluorocarbon coatings. Appl. Surf. Sci. 2015, 359, 380–387.
77. Bao C, Zhu L, Lin Q, Tian H. Building biomedical materials using photochemical bond cleavage. Adv. Mater. 2015, 27, 1647–1662.
78. Fomina N, Sankaranarayanan J, Almutairi A. Photochemical mechanisms of light-triggered release from nanocarriers. Adv. Drug Deliv. Rev. 2012, 64, 1005–1020.
79. Rwei AY, Wang W, Kohane DS. Photoresponsive nanoparticles for drug delivery. Nano Today 2015, 10, 451–467.10.1016/j.nantod.2015.06.004 ↗
80. Baek S, Phan MD, Lee J, Shin K. Packing effects on polymerization of diacetylene lipids in liposomes and monolayers matrices. Polym. J. 2016, 48, 457–463.
81. Wöll D, Smirnova J, Galetskaya M, Prykota T, Bühler J, Stengele K-P, Pfleiderer W, Steiner UE. Intramolecular sensitization of photocleavage of the photolabile 2-(2-nitrophenyl)propoxycarbonyl (NPPOC) protecting group: photoproducts and photokinetics of the release of nucleosides. Chemistry 2008, 14, 6490–6497.10.1002/chem.200800613 ↗
82. Yavlovich A, Singh A, Blumenthal R, Puri A. A novel class of photo-triggerable liposomes containing DPPC: DC 8, 9 PC as vehicles for delivery of doxorubcin to cells. Biochim. Biophys. Acta (BBA)-Biomembranes 2011, 1808, 117–126.10.1016/j.bbamem.2010.07.030 ↗
83. Shum P, Kim J-M, Thompson DH. Phototriggering of liposomal drug delivery systems. Adv. Drug Deliv. Rev. 2001, 53, 273–284.
84. Wang Y, Han P, Xu H, Wang Z, Zhang X, Kabanov AV. Photocontrolled self-assembly and disassembly of block ionomer complex vesicles: a facile approach toward supramolecular polymer nanocontainers. Langmuir 2009, 26, 709–715.10.1021/la9023844 ↗
85. Hester TJ, Dennison SR, Baker MJ, Snape TJ. Functionalising the azobenzene motif delivers a light-responsive membrane-interactive compound with the potential for photodynamic therapy applications. Org. Biomol. Chem. 2015, 13, 8067–8070.
86. Yao C, Wang P, Li X, Hu X, Hou J, Wang L, Zhang F. Near-infrared-triggered azobenzene-liposome/upconversion nanoparticle hybrid vesicles for remotely controlled drug delivery to overcome cancer multidrug resistance. Adv. Mater. 2016, 28, 9341–9348.
87. Wei Y-B, Tang Q, Gong C-b, Lam MH-W. Review of the recent progress in photoresponsive molecularly imprinted polymers containing azobenzene chromophores. Anal. Chim. Acta 2015, 900, 10–20.10.1016/j.aca.2015.10.022 ↗
88. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 2014, 53, 12320–12364.
89. Ishii Ki, Hamada T, Hatakeyama M, Sugimoto R, Nagasaki T, Takagi M. Reversible control of exo- and endo-budding transitions in a photosensitive lipid membrane. ChemBioChem 2009, 10, 251–256.10.1002/cbic.200800482 ↗
90. Xia Y, Yang P, Sun Y, Wu Y, Mayers B, Gates B, Yin Y, Kim F, Yan H. One-dimensional nanostructures: synthesis, characterization, and applications. Adv. Mater. 2003, 15, 353–389.
91. Eustis S, El-Sayed MA. Why gold nanoparticles are more precious than pretty gold: noble metal surface plasmon resonance and its enhancement of the radiative and nonradiative properties of nanocrystals of different shapes. Chem. Soc. Rev. 2006, 35, 209–217.
92. Link S, El-Sayed MA. Shape and size dependence of radiative, non-radiative and photothermal properties of gold nanocrystals. Int. Rev. Phys. Chem. 2000, 19, 409–453.
93. Guo H, Kim J-C. Photothermally induced release from liposome suspended in mixture solution of gold nanoparticle and thermo-sensitive polymer. Colloids Surf. A Physicochem. Eng. Asp. 2015, 469, 73–82.
94. Kalber TL, Ordidge KL, Southern P, Loebinger MR, Kyrtatos PG, Pankhurst QA, Lythgoe MF, Janes SM. Hyperthermia treatment of tumors by mesenchymal stem cell-delivered superparamagnetic iron oxide nanoparticles. Int. J. Nanomed. 2016, 11, 1973.
95. Ma N, Jiang YW, Zhang X, Wu H, Myers JN, Liu P, Jin H, Gu N, He N, Wu FG, Chen Z. Enhanced radiosensitization of gold nanospikes via hyperthermia in combined cancer radiation and photothermal therapy. ACS Appl. Mater. Interfaces 2016, 8, 28480–28494.10.1021/acsami.6b10132 ↗
96. Wu G, Mikhailovsky A, Khant HA, Fu C, Chiu W, Zasadzinski JA. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J. Am. Chem. Soc. 2008, 130, 8175–8177.
97. Lajunen T, Viitala L, Kontturi L-S, Laaksonen T, Liang H, Vuorimaa-Laukkanen E, Viitala T, Le Guével X, Yliperttula M, Murtomäki L, Urtti A. Light induced cytosolic drug delivery from liposomes with gold nanoparticles. J. Control. Release 2015, 203, 85–98.10.1016/j.jconrel.2015.02.028 ↗
98. Drummond DC, Zignani M, Leroux J-C. Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid Res. 2000, 39, 409–460.
99. Karanth H, Murthy R. pH-sensitive liposomes-principle and application in cancer therapy. J. Pharm. Pharmacol. 2007, 59, 469–483.
100. Ferreira DdS, Lopes SCdA, Franco MS, Oliveira MC. pH-sensitive liposomes for drug delivery in cancer treatment. Ther. Deliv. 2013, 4, 1099–1123.